The outcome of second-look GI endoscopy in persistent gut GVHD post allogeneic stem cell transplantation  by AlOtaibi, Ahmad et al.
Hematol Oncol Stem Cell Ther (2016) 9, 39–40Avai lab le a t www.sc ienced i rec t .com
ScienceDirect
journal homepage: www.elsev ier .com/ locate /hemoncLETTER TO EDITORThe outcome of second-look GI endoscopy
in persistent gut GVHD post allogeneic stem
cell transplantationhttp://dx.doi.org/10.1016/j.hemonc.2015.04.004
1658-3876/ 2015 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
* Corresponding author.
E-mail address: ahanbali@kfshrc.edu.sa (A. Hanbali).Ahmad AlOtaibi, Osama Ali, Said Yousuf Mohamad, Amr Hanbali *King Faisal Specialist Hospital & Research Center, Riyadh, Saudi ArabiaReceived 8 April 2015; accepted 11 April 2015
Available online 30 April 2015Graft-versus-host disease (GVHD) is the most frequent
complication after allogeneic hematopoietic cell transplan-
tation (HCT) [1]. It is a complex disease resulting from donor
T-cell recognition of a genetically disparate recipient that is
unable to reject donor cells after allogeneic HSCT [2]. The
incidence of acute GVHD (aGVHD) is 10–80%, depending
upon the risk factors present [3].
The gastrointestinal (GI) tract is the second most com-
monly involved organ in acute GVHD, with up to 50% of
patients who develop GVHD exhibiting GI involvement. Nau-
sea, watery diarrhea, loss of appetite, bloody or mucoid
stools, and abdominal pain are the primary manifestations
of GI GVHD. However, these symptoms and signs are also
often seen in other GI diseases that may occur at the same
time, including drug toxicity and enteric infections. Some of
this differential diagnosis can mimic histological GVHD [4].
Standard treatment for aGVHD consists of corticos-
teroids, although there is a lack of consensus over optimal
dosing and schedule. Response to corticosteroids is seen in
approximately 50% of patients, and those who fail initial
therapy have high mortality rates [5]. The management of
steroid-refractory GVHD is difficult and involves the use of
highly immunosuppressive medications. Such steroid
resistance may be due to therapy failure, destruction ofintestinal mucosa and/or the coexistence of intestinal
infection [4].
Given that other differential diagnosis or coexistent
pathology require different management programs and
may prove conflicting, the initial diagnosis needs to be con-
firmed again before proceeding to further highly toxic med-
ication. We hypothesize that if the patient fails first line
therapy, endoscopy and biopsy need to be repeated in order
to re-evaluate the underlying causes for persistent
symptoms.
To evaluate this hypothesis, we conducted a retrospec-
tive single center study where we reviewed the charts and
electronic records of 200 patients who developed GI GVHD
and were treated between 1984 and 2013. We looked at
those who had at least two endoscopic evaluations with
repeated biopsy for refractory GI GVHD. A total of 20
patients had two endoscopic studies each, and all of them
were initially diagnosed as acute GI GVHD with various
grades. However, in the second endoscopy, six out of the
20 patients (30%) were found to have concomitant CMV col-
itis, which led to changes in management plans.
Our result supports that of Martı´nez et al [4] whose study
retrospectively evaluated 31 patients with persistent diar-
rhea who underwent more than one endoscopic study. In
22 of 31 patients (71%), Martı´nez et al. found that the histo-
logical findings of the second/third endoscopic biopsies
differed from the findings of the first endoscopy and led
to a therapy change in 77%. The results of both our study
40 A. AlOtaibi et al.and theirs suggest that serial GI endoscopies can be of reli-
able diagnostic value and can have an impact on therapeutic
decision-making for patients with persistent diarrhea after
allo-SCT.
Both studies support the hypothesis that dynamic and
serial diagnostic follow up would be optimal, and that this
is sorely needed for patients who require further immuno-
suppressive therapy.
We have initiated a prospective study to evaluate all
refractory gut GVHD patients with second endoscopies and
tissue biopsies to further evaluate this hypothesis.
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